724 results on '"Armstrong, April"'
Search Results
2. Teledermatology: Practice Models
3. Racial and Gender Disparities in Utilization of Outpatient Total Shoulder Arthroplasties
4. Psoriatic Arthritis: A Comprehensive Review for the Dermatologist. Part II: Screening and Management
5. A Care Coordination Model to Prevent Cardiovascular Events in Patients with Psoriatic Disease: A Multicenter Pilot Study
6. Shared decision-making in psoriasis care: Evaluation of how patients’ perception of clinicians’ delivery of care changes by age and sex
7. Brodalumab: 5-Year US Pharmacovigilance Report
8. Consensus Statements on the Use of Novel Formulations of Isotretinoin: A Modified Delphi Process
9. The Most Effective Corticosteroid Dose in the Treatment of Glenohumeral Osteoarthritis: Feasibility Pilot and Protocol for Double Blinded Randomized Controlled Trial
10. Elbow Dislocation
11. An OX-Tra’Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis
12. Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial
13. Bimekizumab Efficacy through Year 1 in Patients with Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3/3B Trials
14. Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program
15. Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials
16. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch as Assessed by the Psoriasis Symptoms and Signs Diary
17. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis
18. Executive Summary: From the Medical Board of the National Psoriasis Foundation: Perioperative management of immunomodulatory agents in patients with psoriasis and psoriatic arthritis
19. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type
20. Comparing Cosmetic Outcomes of Straight-Line Versus W-Plasty Techniques for Linear Postauricular Wound Closure: A Randomized Evaluator Blind Split-Scar Trial
21. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation
22. 516 - Comparative efficacy of targeted systemic therapies with topical corticosteroids for moderate-to-severe atopic dermatitis: an updated network meta-analysis
23. Demographics and Baseline Characteristics of Children With Atopic Dermatitis Enrolled in a Randomized Phase 3 Study (TRuE-AD3)
24. 496 - Conjunctivitis does not increase with longer duration of lebrikizumab exposure in patients with moderate-to-severe atopic dermatitis
25. 557 - Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE study in the United States
26. 556 - A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany
27. 515 - Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis
28. 524 - Efficacy of upadacitinib and dupilumab on achieving stringent and composite skin and itch outcomes: an indirect comparison of adults with moderate-to-severe atopic dermatitis
29. Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis
30. Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey
31. Bimekizumab Efficacy in Patients with Moderate to Severe Plaque Psoriasis and Hypertension, Elevated Body Mass Index, or Hyperglycemia: Results Through 3 years of Treatment in 5 Phase 3/3b Trials
32. Bimekizumab 3-year Maintenance of Response in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from Five Phase 3/3b Trials
33. Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
34. Predictors of dislocations after reverse shoulder arthroplasty: a study by the ASES complications of RSA multicenter research group
35. Tips, Trends, and Truths: A Study of Psoriasis Treatment Content on TikTok
36. Malignancy Risks of Dermatologic Therapies
37. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary
38. Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
39. Trends in Patch-Test Positivity to Methylchloroisothiazolinone and Methylisothiazolinone Based on Regulatory Status: A Systematic Review
40. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor
41. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor
42. Risk factors of acromial and scapular spine stress fractures differ by indication: a study by the ASES Complications of Reverse Shoulder Arthroplasty Multicenter Research Group
43. Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids
44. Evaluation of DermSat-7 for Assessing Treatment Satisfaction in Patients with Acne
45. Rapid and Early Onset of Itch Relief with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to Two Years of Age with Atopic Dermatitis
46. Real-World Switch Rates for Patients With Psoriasis Initiating Risankizumab Stratified by Body Mass Index
47. Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
48. Treatment or Psoriasis with Calcipotriene and Betamethasone Dipropionate (CAL/BDP) Cream Showed Significantly Higher Proportion of Patients with an Absolute mPASI≤2 Compared to CAL/BDP Gel/Topical Suspension in a Post-Hoc Aanalysis of Two Phase 3 Studies
49. Safety and Tolerability of Tirbanibulin 1% Treatment of Actinic Keratosis on Face and Scalp in Routine Clinical Practice Across the U.S. (PROAK Study)
50. Patient- and Clinician-Reported Outcomes of Tirbanibulin 1% in the Treatment of Actinic Keratosis on the Face and Scalp (PROAK Study)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.